Literature DB >> 19643948

Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome.

V Cottin1, J Le Pavec, G Prévot, H Mal, M Humbert, G Simonneau, J-F Cordier.   

Abstract

This study aims to describe the haemodynamic and survival characteristics of patients with pulmonary hypertension in the recently individualised syndrome of combined pulmonary fibrosis and emphysema. A retrospective multicentre study was conducted in 40 patients (38 males; age 68+/-9 yrs; 39 smokers) with combined pulmonary fibrosis and emphysema, and pulmonary hypertension at right heart catheterisation. Dyspnoea was functional class II in 15%, III in 55% and IV in 30%. 6-min walk distance was 244+/-126 m. Forced vital capacity was 86+/-18%, forced expiratory volume in 1 s 78+/-19%, and carbon monoxide diffusion transfer coefficient 28+/-16% of predicted. Room air arterial oxygen tension was 7.5+/-1.6 kPa (56+/-12 mmHg). Mean pulmonary artery pressure was 40+/-9 mmHg, cardiac index 2.5+/-0.7 L x min(-1) x m(-2) and pulmonary vascular resistance 521+/-205 dyn x s x cm(-5). 1-yr survival was 60%. Higher pulmonary vascular resistance, higher heart rate, lower cardiac index and lower carbon monoxide diffusion transfer were associated with shorter survival. Patients with combined pulmonary fibrosis and emphysema syndrome and pulmonary hypertension confirmed by right heart catheterisation have a dismal prognosis despite moderately altered lung volumes and flows and moderately severe haemodynamic parameters.

Entities:  

Mesh:

Year:  2009        PMID: 19643948     DOI: 10.1183/09031936.00038709

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  91 in total

1.  Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.

Authors:  Osamu Nishiyama; Ryo Yamazaki; Akiko Sano; Toshiyuki Yamagata; Hiroyuki Sano; Takashi Iwanaga; Yuji Higashimoto; Hiroaki Kume; Yuji Tohda
Journal:  Chron Respir Dis       Date:  2015-09-15       Impact factor: 2.444

2.  Visually stratified CT honeycombing as a survival predictor in combined pulmonary fibrosis and emphysema.

Authors:  Yong Seek Kim; Gong Yong Jin; Kum Ju Chae; Young Min Han; Su Bin Chon; Young Sun Lee; Keun Sang Kwon; Hye Mi Choi
Journal:  Br J Radiol       Date:  2015-09-21       Impact factor: 3.039

3.  [Interstitial lung diseases (ILD) in smokers: spectrum in high resolution computed tomography (HRCT)].

Authors:  K Marten-Engelke
Journal:  Radiologe       Date:  2013-09       Impact factor: 0.635

4.  Reliance on Pulmonary Function Tests in Assessment of Systemic Sclerosis Patients for Pulmonary Hypertension: Comment on the Article by Antoniou et al.

Authors:  Lesley Ann Saketkoo; Virginia D Steen; Matthew R Lammi
Journal:  Arthritis Rheumatol       Date:  2017-01       Impact factor: 10.995

Review 5.  Pulmonary hypertension in chronic obstructive pulmonary disease and emphysema patients: prevalence, therapeutic options and pulmonary circulatory effects of lung volume reduction surgery.

Authors:  Isabelle Opitz; Silvia Ulrich
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

6.  Surgical Outcomes of Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema and Those with Idiopathic Pulmonary Fibrosis without Emphysema.

Authors:  Seijiro Sato; Terumoto Koike; Takehisa Hashimoto; Hiroyuki Ishikawa; Akira Okada; Takehiro Watanabe; Masanori Tsuchida
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-04-05       Impact factor: 1.520

7.  More on idiopathic pulmonary arterial hypertension with a low diffusing capacity.

Authors:  Karen M Olsson; Jan Fuge; Katrin Meyer; Tobias Welte; Marius M Hoeper
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 8.  Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone.

Authors:  Huijin Lin; Shanping Jiang
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

9.  Respiratory impairment and COPD hospitalisation in older persons: a competing risk analysis.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Thomas M Gill
Journal:  Eur Respir J       Date:  2012-01-20       Impact factor: 16.671

Review 10.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.